Physician Diagnosis and Knowledge of Mild Cognitive Impairment

Emilie M Blair1, Darin B Zahuranec1,2, Jane Forman1,3

  • 1Department of Internal Medicine and Cognitive Health Services Research Program, University of Michigan, Ann Arbor, MI, USA.

Abstract

Insights

Physicians show a poor understanding of mild cognitive impairment (MCI), struggling to distinguish it from dementia. This knowledge gap impacts treatment decisions for older adults, highlighting a need for improved physician education on MCI.

Area of Science:

  • Gerontology
  • Neurology
  • Internal Medicine

Background:

  • Older adults with mild cognitive impairment (MCI) receive suboptimal guideline-concordant treatments compared to those with normal cognition.
  • The reasons behind this treatment disparity in older adults with MCI remain largely unexplained.

Purpose of the Study:

  • To investigate physician understanding and experience with mild cognitive impairment (MCI) in older adults.
  • To assess physician identification of MCI, differentiation from dementia, and perspectives on relevant education and training.

Main Methods:

  • A descriptive qualitative study utilizing semi-structured interviews with 22 physicians (cardiologists, neurologists, internists).
  • The study assessed physician identification of MCI and awareness of MCI/dementia within their specialties.

Main Results:

  • Physicians demonstrated a lack of adequate understanding distinguishing MCI from dementia.
  • Significant variation exists in how physicians identify MCI in older adult patients.
  • Physicians reported varying approaches to identifying MCI in clinical practice.

Conclusions:

  • Physician understanding of MCI is inadequate, impacting clinical practice.
  • Interventions are necessary to enhance physician knowledge and diagnostic skills regarding MCI.
  • Improved physician education on MCI is crucial for equitable treatment of older adults.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
736
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
213
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
232
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
370
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
290
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
203